A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

* Have a diagnosis of chronic plaque psoriasis for at least 6 months before the first administration of study drug. Duration since diagnosis may be reported by the participant * Participant has stable moderate to severe plaque psoriasis (body surface area \[BSA\] \>10, Psoriasis Area and Severity Index \[PASI\] \>10, and Dermatology Quality of Life Index \[DLQI\] \>10) with or without psoriatic arthritis at Baseline * Must be naïve to and candidate for systemic therapy, as assessed by the investigator * Participant has an inadequate response, intolerance or contraindication to topical psoriasis treatment

* Participants with non-plaque forms of psoriasis * Participant has previously received systemic therapy for psoriasis, whether biologic or non-biologic or photochemotherapy * Active systemic infection during the last 2 weeks (exception: common cold) prior to screening. * Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix * Participant has any condition or contraindication to Fumaderm that would preclude the patient's participation in the present study